妊娠11-13周筛查子痫前期:妊娠相关血浆蛋白A、胎盘生长因子或两者联合应用
本研究基于60875例单胎妊娠的前瞻性筛查数据,采用竞争风险模型联合母体因素、平均动脉压、子宫动脉搏动指数及血清标志物评估早产子痫前期风险。结果显示,联合胎盘生长因子(PlGF)的筛查效果优于联合妊娠相关血浆蛋白A(PAPP-A):在10%筛查阳性率下,前者对<37周子痫前期的检出率为74.1%,比后者高7.1%(95%CI 3.8-10.6%)。加用PAPP-A并不能改善包含PlGF的模型的预测性能。
要点
- 早孕期筛查子痫前期首选生化标志物为PlGF而非PAPP-A。
- 在10%筛查阳性率下,含PlGF方案对<37周子痫前期的检出率比含PAPP-A方案高7.1%。
- 若使用PAPP-A替代PlGF,达到相同检出率需更高的筛查阳性率。
核心结论
- 在早孕期子痫前期筛查中,首选的生化标志物是PlGF而非PAPP-A。
- 若使用PAPP-A替代PlGF,可达到相同的检出率,但筛查阳性率更高。
研究设计与样本
- 非干预性筛查研究,数据来自单胎妊娠孕妇常规早孕期就诊的前瞻性不良产科结局筛查。
- 研究人群共60875例单胎妊娠,其中1736例(2.9%)发生子痫前期。
- 采用竞争风险模型,结合母体特征与病史得出的子痫前期分娩孕周先验分布,与MAP、UtA-PI、PlGF和PAPP-A的MoM值相乘,计算<37周子痫前期分娩的患者个体化风险。
- 在总人群及白人和黑人种族亚组中评估筛查性能,采用McNemar检验比较固定筛查阳性率下含与不含PlGF和PAPP-A的筛查检出率。
诊断标准与关键数值
- 在筛查阳性率10%下,联合母体因素、MAP、UtA-PI和PlGF对<37周子痫前期的检出率为74.1%,比联合母体因素、MAP、UtA-PI和PAPP-A高7.1%(95%CI 3.8-10.6%)。
- 白人女性中,联合母体因素、MAP、UtA-PI和PlGF筛查,若期望早产子痫前期检出率为75%,风险截断值应为1/136,筛查阳性率为14.1%。
- 黑人女性中,联合母体因素、MAP、UtA-PI和PlGF筛查,若期望检出率为75%,风险截断值应为1/29,筛查阳性率为12.5%。
- 白人女性中,联合母体因素、MAP、UtA-PI和PAPP-A筛查,若期望检出率为75%,风险截断值应为1/140,筛查阳性率为16.9%。
- 黑人女性中,联合母体因素、MAP、UtA-PI和PAPP-A筛查,若期望检出率为75%,风险截断值应为1/44,筛查阳性率为19.3%。
临床应用与阅片要点
- 早孕期子痫前期筛查模型应优先纳入PlGF而非PAPP-A。
- 风险截断值和筛查阳性率需根据研究人群的种族构成及所用生化标志物进行调整。
- 若因故使用PAPP-A替代PlGF,需预期在相同检出率下筛查阳性率会升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: First-trimester screening for pre-eclampsia (PE) is useful because treatment of the high-risk group with aspirin reduces the rate of early PE with delivery at < 34 weeks' gestation by about 80% and that of preterm PE with delivery at < 37 weeks by 60%. In previous studies, we reported that the best way of identifying the high-risk group is by a combination of maternal factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and serum placental growth factor (PlGF). An alternative biochemical marker is pregnancy-associated plasma protein-A (PAPP-A), which is used widely as part of early screening for trisomy. The objective of this study was to examine the additive value of PlGF and PAPP-A in first-trimester screening for preterm PE by maternal factors, MAP and UtA-PI and define the risk cut-off and screen-positive rate to achieve a desired detection rate of PE if PAPP-A rather than PlGF was to be used for first-trimester screening.
METHODS: This was a non-intervention screening study. The data were derived from prospective screening for adverse obstetric outcomes in women with singleton pregnancy attending for a routine first-trimester hospital visit. Patient-specific risks of delivery with PE at < 37 weeks' gestation were calculated using the competing-risks model to combine the prior distribution of gestational age at delivery with PE, obtained from maternal characteristics and medical history, with multiples of the median (MoM) values of MAP, UtA-PI, PlGF and PAPP-A. The performance of screening in the total population and in subgroups of women of white and black racial origin was estimated. McNemar's test was used to compare the detection rate, for a fixed screen-positive rate, of screening with and without PlGF and PAPP-A. Risk cut-offs and screen-positive rates to achieve desired detection rates of preterm PE were determined in screening with and without PlGF and PAPP-A.
RESULTS: The study population was composed of 60 875 singleton pregnancies, including 1736 (2.9%) that developed PE. There are three main findings of this study. First, the performance of first-trimester screening for PE by a combination of maternal factors, MAP, UtA-PI and PlGF is superior to that of screening by maternal factors, MAP, UtA-PI and PAPP-A; for example, in screening by maternal factors, MAP, UtA-PI and PlGF, at a screen-positive rate of 10%, the detection rate of PE with delivery at < 37 weeks' gestation was 74.1%, which was 7.1% (95% CI, 3.8-10.6%) higher than in screening by maternal factors, MAP, UtA-PI and PAPP-A. Second, addition of serum PAPP-A does not improve the prediction of PE provided by maternal factors, MAP, UtA-PI and PlGF. Third, the risk cut-off and screen-positive rate to achieve a given fixed detection rate of preterm PE vary according to the racial composition of the study population and whether the biomarkers used for screening are MAP, UtA-PI and PlGF or MAP, UtA-PI and PAPP-A. For example, in screening by a combination of maternal factors, MAP, UtA-PI and PlGF in white women, if the desired detection rate of preterm PE was 75%, the risk cut-off should be 1 in 136 and the screen-positive rate would be 14.1%; in black women, to achieve a detection rate of 75%, the risk cut-off should be 1 in 29 and the screen-positive rate would be 12.5%. In screening by a combination of maternal factors, MAP, UtA-PI and PAPP-A in white women, if the desired detection rate of preterm PE was 75%, the risk cut-off should be 1 in 140 and the screen-positive rate would be 16.9%; in black women, to achieve a detection rate of 75%, the risk cut-off should be 1 in 44 and the screen-positive rate would be 19.3%.
CONCLUSION: In first-trimester screening for PE, the preferred biochemical marker is PlGF rather than PAPP-A. However, if PAPP-A was to be used rather than PlGF, the same detection rate can be achieved but at a higher screen-positive rate. © 2020 Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Mazer Zumaeta A, Wright A, Syngelaki A, et al. Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both. Ultrasound Obstet Gynecol. 2020. PMID: 32441401. doi:10.1002/uog.22093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。